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Abstract
Background: The recent development of new high-throughput technologies for SNP genotyping has
opened the possibility of taking a genome-wide linkage approach to the search for new candidate genes
involved in heredity diseases. The two major breast cancer susceptibility genes BRCA1 and BRCA2 are
involved in 30% of hereditary breast cancer cases, but the discovery of additional breast cancer
predisposition genes for the non-BRCA1/2 breast cancer families has so far been unsuccessful.
Results: In order to evaluate the power improvement provided by using SNP markers in a real situation,
we have performed a whole genome screen of 19 non-BRCA1/2 breast cancer families using 4720
genomewide SNPs with Illumina technology (Illumina's Linkage III Panel), with an average distance of 615
Kb/SNP. We identified six regions on chromosomes 2, 3, 4, 7, 11 and 14 as candidates to contain genes
involved in breast cancer susceptibility, and additional fine mapping genotyping using microsatellite
markers around linkage peaks confirmed five of them, excluding the region on chromosome 3. These
results were consistent in analyses that excluded SNPs in high linkage disequilibrium. The results were
compared with those obtained previously using a 10 cM microsatellite scan (STR-GWS) and we found
lower or not significant linkage signals with STR-GWS data compared to SNP data in all cases.
Conclusion: Our results show the power increase that SNPs can supply in linkage studies.
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Background
Genomewide linkage scans have traditionally been per-
formed using low-density maps of microsatellite markers
with a spacing of about 10 cM across the genome [1].
However, the recent development of new high-through-
put technologies for SNP genotyping has opened up the
possibility of taking a genome-wide approach to study
polymorphisms quickly and economically. Moreover,
several studies have demonstrated that a map of very
closely spaced SNP markers could offer many advantages
over the low density maps of microsatellite markers,
mainly by increasing the power to detect linkage and con-
sequently more precisely identify the disease locus [2-7].
Although these biallelic markers have lower heterozygos-
ity, they are at a higher density in the genome and they are
associated with lower genotyping error rates [8,9]. Addi-
tionally, SNP assays are more amenable to multiplexing
and are easier to automate, and over 6 million validated
human SNPs have been stored in public databases to date.
Genomewide linkage scans have become a widely used
tool in the effort to unravel the genetic bases of human
hereditary diseases. One example of this is the search for
high-penetrance genes involved in breast cancer. The two
major breast cancer susceptibility genes, BRCA1 and
BRCA2, have been shown to be involved in a significant
proportion of families affected with breast and ovarian
cancer, but it is clear that about 70% of familial breast
cancer is not caused by mutations in these genes [10-13].
These families are known as BRCAX families. Unfortu-
nately, despite intensive efforts, the discovery of addi-
tional breast cancer predisposition genes has so far been
unsuccessful. [14-16]. Recently, a large linkage scan study
of the BCLC (Breast Cancer Linkage Consortium) which
included 149 BRCAX families and used traditional micro-
satellite markers (450 Short Tandem Repeats or STRs)
failed to identify any candidate regions that were signifi-
cant at a genome-wide level [16], presumably because of
possible genetic heterogeneity of these families and/or
because of recessive/polygenic mechanisms [15,16]. Alter-
natively, significant linkage may have been missed as a
result of sub-optimal coverage of the genome by the STR
marker set used, which may not have extracted all the
inheritance information contained in the dataset.
Therefore, we have conducted a linkage study with 4.720
SNPs across the genome in nineteen BRCAX families to
identify candidate regions containing BRCAX gene(s). We
show the existence of different candidate regions linked to
a small number of families, and a power improvement by
using SNPs instead of microsatellite markers.
Results
Candidate regions
Results of multipoint non parametric linkage analysis
(NPLA) in all chromosomes for our SNP data (SNP-GWS)
are shown in Figure 1 (using ALL frequencies; see meth-
ods). Candidate linkage regions were determined as those
Multipoint nonparametric linkage analysis of 19 families Figure 1
Multipoint nonparametric linkage analysis of 19 families. The figure includes LOD scores (top) and information con-
tent (bottom) using CEPH and ALL frequencies. Chromosome numbers are indicated below each panel.BMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
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with an NPLOD score with p-values ≤ 0.01 using CEPH
frequencies (see methods), but that were still significant
(p-values ≤ 0.05) when more conservative analysis using
ALL frequencies was done.
Six regions on six different chromosomes were selected
according this criteria to contain susceptibility genes
involved in breast cancer using both CEPH and ALL fre-
quencies: chromosome 2, with a maximum NPLOD score
of 2.26 and 1.70 (p-values ≤ 0.01 and 0.04 respectively);
chromosome 3 with a maximum NPLOD score of 2.29
and 2.19 (p-values ≤ 0.01); chromosome 4 with a maxi-
mum NPLOD score of 2.29 and 2.01(p-values ≤ 0.01 and
0.02 respectively); chromosome 7 with a maximum
NPLOD score of 2.56 and 2.44 (p-values ≤ 0.01); chromo-
some 11 with a maximum NPLOD score of 2.21 and 2.15
(p-values ≤ 0.01 and 0.02 respectively) and chromosome
14 with a maximum NPLOD score of 2.25 and 1.89 (p-
values ≤ 0.01 and 0.02 respectively. Although the telom-
eric region of chromosome 8 also fulfilled the criteria to
be considered a candidate region, telomeric regions are
prone to show inflated LOD score values and this region
was therefore not investigated further [see Additional file
1]. In addition, two more regions in chromosome X were
identified with NPLOD score with p-values ≤ 0.01 using
CEPH frequencies, neither of them were considered
because they were not significant when ALL frequencies
were applied.
Maximum NPLOD scores and parametric HLOD scores
(both dominant and recessive models) for these regions
using ALL frequencies are summarized in Table 1.
Only a small fraction of families showed significant link-
age values (p < 0.05) in these regions when NPLOD score
per Family was calculated. Three families were selected in
candidate regions in chromosome 3, 4 and 7 with moder-
ate linkage values (from 1.89, p < 0.03, to 5.00 p <
0.00001, in NPL analysis) and a single family with very
high NPLOD score value (higher that 5.52 p < 0.00001 to
11.40 p < 0.000001, in NPL analysis) in chromosome 2,
11 and 14 was found (see Table 2). These families with
significant NPLOD scores were considered as a linked
family in these candidate regions and included in the next
fine mapping step using microsatellite markers.
Impact of LD on linkage results
The inflation of the nonparametric multipoint LOD score
due to inter-marker linkage disequilibrium (LD) has been
recently described [17,18], and so inter-marker LD should
be taken into account in our high-density genome-wide
SNP linkage screen. Two analyses were performed to asses
whether LD affected linkage results in our data, using two
different approaches to dealing with LD. Figure 2A shows
the comparison of NPLOD score values in the six candi-
date regions selected using ALL frequencies, taking into
account different measures of LD between marker loci (r2
> 0.2/0.5/0.8); the same regions are shown in Figure 2B
using different marker densities (0.5 cM/1 cM/2 cM). The
same six regions were still identified when discarding
markers correlated with different r2 values (0.2/0.5/0.8),
that is, almost all candidate regions are maintained with
significant p values (p < 0.05) in all analyses (except chro-
mosome 2, using r2 = 0.5 and 0.2). The other method to
discard possible markers in LD was to take the genetic dis-
tance between them into consideration. We found a more
drastic decrease in the NPLOD scores when this approach
was used. The information content (IC) value was also
calculated and compared for both analyses. In additional
information [see Additional file 2] is summarized the
number of markers used in all the analysis after removing
the markers. Figure 2 shows that the decrease of this value
in all regions is higher when the genetic distance between
markers is considered than when LD values are considered
[see also Additional file 3 for more details; values for
Table 1: Maximum LOD score in candidate regions
CHR Region From To NPL p value PAR DOM PAR REC
SNP cM SNP cM
2 2p22.3 rs1054889 56 rs1167465 62
3 3p21.31p14.
3
rs1014228 67 rs920891 70 2.19 0.014 0.74 NL
4 4p14q12 rs1046655 51 rs2538 64 2.01 0.02 1.31 1.12
7 7q21.11q21.
3
rs2040902 95 rs722263 105 2.44 0.007 1.02 1.57
11 11q12.3q14.
3
rs1525064 67 rs1404532 91 2.15 0.02 1 NL
14 14q13.1q21.
3
rs2027338 34 rs1532202 43 1.89 0.03 1 NL
LOD score values under the dominant (PAR DOM), recessive (PAR REC), and nonparametric (NPL) analysis with the p-values of the SNP-GWS in 
19 BRCAX families using ALL frequencies. NL: no linkage (values < 1 in parametric analysis)BMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
Page 4 of 13
(page number not for citation purposes)
NPLOD score using ALL frequencies, p-values and IC in
both methods are shown].
Simulation results
We have calculated how many regions with similar
NPLOD scores could be expected by chance, in order to
examine the false positive rates in our data. Gene drop-
ping simulations were performed. This analysis replaces
our real data with simulated chromosomes, maintaining
the original pedigree structure, allele frequencies and
recombination fraction, and retaining the original miss-
ing data patterns. These datasets are generated under the
null hypothesis of no linkage or association to observed
phenotypes. Using Merlin software, we generated 1000
random genomewide scan replicates of the data and those
regions with an NPLOD score with p-values ≤ 0.01 using
CEPH frequencies and were still significant (p-values ≤
0.05) when more conservative analysis using ALL frequen-
cies was done, were computed (according the criteria
applied in our candidate region selection).
The distribution of the number of candidate regions iden-
tified according these criteria from 1000 randomly simu-
lated genomewide scans is shown [see Additional file 4].
We observed that only 15 replicate scans showed positive
scores greater than or equal to seven (the number of
regions originally identified in the real data) [see Addi-
tional file 1], giving an empirica p-value of 0.015. The
results found with the simulated data suggest more allele
sharing in our data than would be expected by chance.
Fine mapping analysis in candidate regions
Wiltshire et al. [19] demonstrated that true positive peaks
are more prone to increase in LOD score when additional
informative meioses are sampled, while false positives are
not. Although a peak increase in fine mapping is not a
proof that the signal is real, the magnitude of the increase
is proportional to the increase in the probability of link-
age while a peak decrease is associated with a decrease in
the subsequent probability of linkage. In order to confirm
or discard our peaks in the candidate regions, we did an
additional genotyping in these regions with STRs. A total
of 50 further STR markers were analysed in the families
that had shown positive model-free LOD score values in
the candidate regions. The mean and median distances
between STRs across candidate regions were 2.5 cM (2.7
Mb) and 2.2 cM (2.3 Mb) respectively. The corresponding
values for the SNPs-STRs combined in the fine mapping
were 0.9 cM (1.0 Mb) and 0.6 cM (0.7 Mb) respectively
across candidate regions.
Maximum NPLOD score comparison in individual fami-
lies with and without fine-scale markers in our candidate
regions are shown in Table 2. We found that linkage anal-
ysis including microsatellite markers across the candidate
regions showed differences in the maximum LOD score
values, either confirming (2p22.3, 4p14q12 7q21.11–
Table 2: Maximum NPLOD score values for linkage families in the candidate regions
CHR FAMILY From To SNP-GWS p value SNP-GWS 
+ STRs
p value
SNP cM SNP cM
2 3395 rs714513 50.2 rs1167465 61.6
3 154* rs4796 54.5 rs2030395 68.5 4.07 0.00001 1.90 0.03
3 2191* rs893367 67.5 rs1392702 70.7 2.06 0.02 0.17 0.4
3 3395* rs1127732 56 rs1024008 94.5 2.38 0.01 0.64 0.3
4 8 rs936232 37.1 rs894905 60.5 2.22 0.01 2.23 0.01
4 14* rs12142 49 rs1560605 74.1 3.03 0.001 0.27 0.4
4 2191 rs1456087 39.7 rs1560605 74.1 5.00 0.00001 4.98 0.00001
7 14* rs917424 88.3 rs875588 164.2 3.42 0.0005 2.84 0.003
7 3386 rs2009526 76.6 rs1990790 134.2 1.89 0.03 1.84 0.03
7 3568 rs917089 98.3 rs322812 131.3 2.33 0.01 2.33 0.01
11 153 rs1675090 66.6 rs586699 92.3 11.40 0.000001 11.47 0.000001
14 153 rs2027338 34.2 rs923908 44 10.50 0.000001 11.53 0.000001
Two different sets of markers are considered: a) SNP-GWS, b) SNP-GWS plus STR fine mapping. *Families ruled out after STR fine mapping.BMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
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LOD score values and information content Figure 2
LOD score values and information content. LOD score values (top part of each panel) and information content (bottom 
part of each panel) in the six candidate regions selected, taking into account: A) LD between marker loci (r2 > 0.2/0.5/0.8), and 
B) marker densities (0.5 cM/1 cM/2 cM).BMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
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7q21.3, 11q13.5–11q14.3 and 14q21.1–14q21.3
regions) or ruling out (3p21.31–3p14.3 region) our can-
didate regions. Therefore, rather than narrowing the
regions, the fine mapping analysis led to the identification
of well-defined positive areas in some regions where the
LOD score increases or at the very least remains the same,
and ruled out other areas where the LOD values drop. Five
of six regions were maintained after the analysis but fam-
ily 14 was ruled out in the candidate regions on chromo-
somes 4 and 7. Moreover, the candidate regions on
chromosome 3 in all families were ruled out too. A final
number of five regions (in chromosome 2, 4, 7, 11 and
14) are proposed as new putative loci to contain suscepti-
bility breast cancer genes.
SNPs versus microsatellites comparison
Firstly, the data quality was extremely high with successful
genotyping obtained for 98.9% of SNP markers compared
to STR call rate of 96.7%.
Secondly, in order to evaluate whether a map of closely
spaced SNPs offers equal or higher power to detect linkage
compared with the traditional approach based on STR-
GWS, we compared the linkage values obtained along
these six candidate regions. Parametric and nonparamet-
ric analyses were performed using 16 of the 19 families
with both types of data available, and the nonparametric
NPLOD scores obtained with SNP-GWS and STR-GWS are
shown in Figure 3 (using ALL frequencies estimating by
averaging over all typed individuals). A comparison of
information content is also shown in Figure 3.
In all cases, the lowest NPLOD score values were found
when microsatellite markers were analyzed. When STR
markers were used, the maximum NPLOD scores
obtained with SNPs dropped from 2.25 (p = 0.012) to -
0.21 (p = 0.6) in chromosome 2, 1.90 (p = 0.03) to 0.42
(p = 0.3) in chromosome 3, 2.22 (p = 0.013) to 1.65 (p =
0.05) in chromosome 4, 2.59 (p = 0.005) to 1.77 (p =
0.04) in chromosome 7 and from 2.51 (p = 0.006) and
2.41 (p = 0.008) to 0.53 (p = 0.3) and 0.98 (p = 0.2) in
chromosomes 11 and 14, respectively. Also, our results
suggest that SNP mapping allows loci to be defined more
precisely than STR marker due to the higher marker den-
sity (figure 3).
In order to evaluate the ability of both sets of markers to
identify the candidate regions, we used the inclusion cri-
teria of Smith et al. [16]: linkage peaks with both non par-
ametric and parametric analysis (NPA and PA) LOD
scores greater than 1 for the whole family set (in this case,
16 families), or linkage peak with a parametric LOD score
greater that 1.5 in individual families under the Domi-
nant Model (DM). Comparative results by regions under
NPA (NPLOD score) and PA (HLOD for dominant and
also recessive models) are shown in Table 3. We found
that using SNP data (SNP-GWS), all candidate regions
showed NPLOD score greater that 1 and HLOD values
greater than 1 in all of them except the region in chromo-
some 3. On the other hand, using STR markers, only three
of them would be identified (in chromosome 3, 4 and 7)
with NPA and only chromosome 4 had HLOD values
greater than 1 for both models when PA was performed.
In addition, in Table 4 we summarized those individual
families in these regions with parametric HLOD values
greater than 1.5 that are considered as linkage families
according to Smith et al. [16]. Four families were identi-
fied using the SNP-GWS set (one in each candidate
region) but just two were found when STR-GWS data were
used. When high-density STR data (fine-mapping step)
were included in the analysis, all the HLOD values were
maintained or increased in both SNP-GWS and STR-GWS
data. Under this inclusion criterion, Family 3395 in chro-
mosome 2 and Family 153 in chromosome 14 would not
have been identified if only STR-GWS had been consid-
ered. Moreover, when positive linkage signals using STR-
GWS were found, none of them were higher than those
obtained with SNP-GWS. These results demonstrate that
SNP data would be preferable in order to avoid either sug-
gestive or significant linkage being missed. Finally, when
high-density STR data were included in the analysis, all
the HLOD values were maintained or increased in both
SNP-GWS and STR-GWS data.
Discussion
The results reported here represent one of the first genom-
ewide scans using SNP markers to identify breast cancer
susceptibility loci. We first carried out a SNP-GWS using
data from 19 BRCAX families and identified six candidate
regions. We used both ALL and CEPH frequencies in this
analysis and we found no important differences. This
result demonstrates that data analysis using frequencies
derived from the data itself is very consistent and robust.
We then performed high-density STR mapping with addi-
tional microsatellites across identified linkage peaks in an
attempt to obtain more convincing support for linkage.
We found suggestive evidence of linkage in five of the six
candidate regions: 2p22.3, 4p14q12, 7q21.11–7q21.3,
11q13.5–11q14.3 and 14q21.1–14q21.3.
In parallel, simulated data revealed that only 15 in 1000
genomewide scans would have shown at least as many
positive LOD score values as we obtained, by chance
alone. That is, despite the lack of strong linkage signals in
our data, we observed a higher proportion of sharing than
would be expected by chance, which suggests that some of
our observed candidate peaks could contain susceptibility
loci.BMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
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SNP-GWS versus STR-GWS data Figure 3
SNP-GWS versus STR-GWS data. Comparison of SNP-GWS (black) and STR-GWS (grey) results in candidate regions. 
NPLOD score comparisons are at the top, and information content (IC) comparisons are at the bottom of each panel.
Table 3: Comparative LOD scores in candidate regions using SNP-GWS and STR-GWS data
SNP-GWS STR-GWS
CHR Region NPL p value PAR DOM PAR REC NPL p value PAR DOM PAR REC
2 2p22.3 2.25 0.012 1.45 0.20 -0.21 0.600 0.00 0.00
3 3p21.31p14.
3
1.95 0.030 0.64 0.68 1.01 0.200 0.00 0.16
4 4p14q12 2.22 0.013 1.38 1.40 1.65 0.050 1.34 1.29
7 7q21.11q21.
3
2.59 0.005 1.00 2.01 1.77 0.040 0.48 0.94
11 11q13.5q14.
3
2.51 0.006 1.04 0.20 0.99 0.200 0.84 0.20
14 14q21.1q21.
3
2.41 0.008 1.03 0.30 0.98 0.200 0.75 0.77
Comparative NPLOD scores and PLOD scores (HLOD) under dominant (PAR DOM) and recessive models (PAR REC) using SNP-GWS and STR-
GWS data in candidate regions according to Smith et al [15] (NL: values < 1 in NPLOD or PLOD). Values > 1.00 are highlighted in bold.BMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
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We performed parametric (PA) and nonparametric analy-
ses (NPA). Using PA, no exceptionally strong linkage sig-
nals were found, since this value depends on the assumed
genetic model being correct. This means that evidence for
linkage might be missed if we only perform PA. On the
other hand, using NPA we identified a region in chromo-
some 3 that was later discarded when fine mapping geno-
typing data were considered, but this false positive
evidence of linkage was not found when PA was per-
formed. These results highlight the importance of per-
forming both parametric and non-parametric analyses in
order to avoid false negative and false positive results.
Regarding our candidate regions, in a previous paper
Huusko et al. [15] found a linkage signal in 14 Finnish
breast cancer families in the 2q32 region D2S2262 (190.8
cM), and another one on chromosome 9, close to D9S283
(93.2 cM). We have not replicated these results in our
study which gave evidence at chromosome 2, but in the
2p22.3 region. In addition, a further study has been pub-
lished including exclusively Swedish non-BRCA1/2 fami-
lies and using 10.000 SNPs across the genome [20]. This
study has reported suggestive linkage (HLOD 2.34) to the
10q23.32–q25.2 region as well as two other loci at
12q14–q21 and 19p13.3–q12, but none of these has been
replicated in our study. These results may suggest that
these non replicate regions could be specific of both Finn-
ish and Swedish populations respectively. On the other
hand, no clear locus conferring a substantial risk was iden-
tified in the genome-wide linkage analysis by Smith et al.
[16], even though the number of families was much
higher (149 multiple case breast cancer families). It
should be noted that, despite the large number of families
included, none of the identified regions meet the classic
criteria for significance in linkage for a genomewide link-
age study of a LOD score of 3.0. The highest HLOD was
1.8 on chromosome 4 (D4S392; 79 cM). Four other LOD
score greater that 1 were found on chromosomes 2
(HLOD 1.21; 17 cM), 5 (HLOD 1.04; 196 cM), 14 (NPL
1.56; 44 cM) and 22 (HLOD 1.15; 41 cM). Obviously,
since some families were common in the Smith et al. study
and in our study, we have also identified the same region
on chromosome 4p14q12, but while in Smith et al. [16]
this result is predominantly due to a single family
(FAM2191 in both studies), we have found a second fam-
ily with evidence of linkage in this region after fine map-
ping (FAM8). Not surprisingly, SNP analysis also
identified a linkage signal in the 11q13.5 region for the
family RUL153 that was noted in Smith et al. [16]. Simi-
larly we found a linkage signal at position 34–43 cM in
chromosome 14 (NPL of 1.89), which is close to the locus
(44 cM) previously reported by Smith et al. [15]. We also
detected a signal at chromosome 2 (HLOD of 1.17), but
this was located at position 56 cM, close to marker
rs1054889. Smith et al. [16] found no signal greater than
1 at our candidate region in chromosome 7.
Smith et al. [16] reported that heterogeneity between fam-
ilies could be a explanation for the lack of evidence of
linkage. Polygenic models in which the existence of a large
number of breast cancer susceptibility genes, each one
conferring modest risk for developing the disease have
been also proposed. Recently, Easton et al. [21] have per-
formed a genome-wide case-control breast cancer associa-
tion study that identified five loci containing plausible
causative low-risk variants. However none of our candi-
date regions overlap, probably because linkage approach
lacks power to detect alleles with small effects on disease
risk. Both scenarios would explain the unsuccessful
attempts to identify other breast cancer predisposition
genes different from BRCA1 and BRCA2, due to lack of
power. Therefore, it seems to be crucial to include in
future studies large subsets of families from homogeneous
populations, to reduce the genetic variation and moreover
increase linkage detection power.
Inflation of the linkage signals may arise especially when
intermarker LD is present and pedigree founders are not
available. Two analyses were performed to assess whether
LD affected the linkage results from our data, each using a
Table 4: Comparative LOD scores in linkage families using SNP-GWS and STR-GWS data both with and without high-density STRs 
data
DM HLOD RM HLOD
CHR Family SNP-GWS SNP-GWS + STRs STR-GWS STR-GWS + STRs
2 3395 1.73 1.92 NL NL
4 2191 1.8 1.8 1.74 1.75
11 153 2.2 2.2 1.78 1.98
14 153 2.2 2.2 NL NL
Comparative parametric LOD scores (HLOD) under dominant and recessive models using SNP-GWS and STR-GWS; both with and without high-
density STRs data in linkage families. Candidate families 8, 3386 and 3568 were excluded since none of them had a parametric LOD score greater 
than 1.5. NL: values < 1.5 in parametric analysis according to Smith et al [15]. SNP-GWS + STRs: SNP-GWS plus STR fine mapping. STR-GWS + 
STRs: STR-GWS plus STR fine mapping.BMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
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different approach to exclude SNPs in order to remove
correlated markers. We found that LOD scores were main-
tained when SNPs were excluded based on observed LD
patterns, but when genetic distance was the criterion for
exclusion, it resulted in much lower IC values, suggesting
that it was too severe. Our results demonstrate that mod-
elling marker-marker LD to eliminate redundant SNPs is
sufficient to avoid false positive signals but at the same
time limits the decrease in IC and consequent loss of
power, and therefore seems to be the best strategy for the
optimal use of SNP linkage panels. Besides, the small
number of markers discarded in LD modelling analysis
indicates that only modest LD was present in the Illumina
SNP panel used. Therefore, we can conclude that LD
between loci does not significantly affect the overall detec-
tion of linkage regions in our SNP genome scan.
We have compared results obtained from SNP markers
using the Illumina panel (version III) to those from a tra-
ditional 10 cM microsatellite scan, and we have demon-
strated that dense SNP maps can provide higher power,
identifying regions suggestive of linkage that would be
missed by a standard microsatellite scan. Using this strat-
egy, we have observed a clear improvement in the power
of linkage signal detection because it is noteworthy that
while five regions were consistently identified performing
both parametric and non-parametric analysis of SNP-
GWS data, only one of these was identified when tradi-
tional STR-GWS data were analysed.
Conclusion
In conclusion, our strategy of two-stage linkage mapping,
therefore, has allowed us to identify five new putative loci
related to breast cancer with moderate values that suggests
the existence of genetic heterogeneity among these non-
BRCA1/2 breast cancer families. We also found two
regions (11q13.5 and 14q21.1–14q21.3) linked to the
same family (FAM153) and confirmed these by fine map-
ping analysis. This result is consistent with the hypothesis
of a polygenic model as has been previously suggested.
Therefore, our results show that genomewide scans using
SNP markers, followed by fine mapping using STRs to
confirm the veracity of the primary scan, appears to be an
optimal strategy for future linkage analyses. In addition,
this approach provides more and stronger linkage signals
than those using traditional STR markers and allows both
to screen for well-defined positive areas in some regions,
and to filter any false positive signals.
Methods
Families selected
Nineteen families with non-BRCA1/2 hereditary breast
cancer from the USA, the Netherlands and Spain were
selected for this study. Sixteen of them were previously
genotyped using a low density genomewide scan with
microsatellite markers and most of them were included in
the recent Breast Cancer Linkage Consortium Study [16].
Families had to satisfy the following criteria: a) at least
three women diagnosed with breast cancer below age 60
years, b) no case of ovarian cancer or male breast cancer
in a blood relative, c) DNA samples available for genotyp-
ing from at least three women affected with breast cancer,
or from children of affected individuals such that the gen-
otypes might be inferred (in the latter case, at least two
children of affected women needed to be available). DNA
samples were available from 81 female family members
with breast cancer. The nineteen families were recruited
by three groups. The Spanish families (5 families) were
ascertained by the Familial Cancer Unit at The Spanish
National Cancer Centre (CNIO) in Madrid; the American
families (7 families) were ascertained by Henry Lynch at
Creighton University in Omaha Nebraska and originally
genotyped at the International Agency for Cancer
Research (IARC); and the Dutch families (7 families) were
ascertained by the Clinical Genetic Centres in Leiden and
Rotterdam and through the Netherlands Foundation for
the Detection of Hereditary Tumours (STOET) [see Addi-
tional file 5]. In all cases the DNA of one affected member
of each family was studied, and the presence of BRCA1
and BRCA2 gene mutations was ruled out through differ-
ent methods (sequencing or DHPLC). The presence of
large deletions and insertions was analysed using MLPA
(Multiplex Ligation Probe Amplification), deletion junc-
tion-PCR or Southern analysis.
Markers and genotyping
SNPs markers were genotyped using the Illumina BeadAr-
ray linkage mapping panel (version III). Oligonucleotides
were designed and synthesized by Illumina, Inc. Details of
the GoldenGate assay have been previously described
[22,23]. A total of 4763 genomewide SNPs are included in
the panel, with mean and median physical spacing's of 0.6
Mb and 0.4 Mb, respectively. Mean and median genetic
spacing's were 1.5 cM and 1.1 cM, respectively [24]. Final
markers included in the study are shown [see Additional
file 2].
For sixteen of the nineteen families, a total of 400 poly-
morphic microsatellite or STR markers from the ABI Prism
Linkage Mapping Set-MD10 (Applied Biosystems) were
analysed on ABI 3700 DNA sequencers at the Welcome
Trust Sanger Institute. The average interval between the
markers was 10 cM. Genotypes were called automatically
with Genotyper software.
In addition, in order to narrow down potential regions of
interest based on the analysis of the genomewide SNPs
(GWS-SNPs), we selected STRs with high heterozygosityBMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
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across candidate regions (one every 2–3 cM). Fine density
genotyping around linkage peaks (8 STRs/region on the
average) was performed in families that showed sugges-
tive linkage. Genotyping was performed at the CNIO
using the ABI 3700 DNA sequencer platform and data
analysis was carried out using Genescan software.
Quality control data
To control the quality of experimental variables such as
plate orientation, and to provide the opportunity to test
genotyping reproducibility, inter- and intra-plate dupli-
cate genotyping was performed. The PEDSTATS software
was used to determine the genotyping success rate, to con-
firm the pedigree structure, and to correctly specify the
relationships between individuals in each family [25]. The
PEDCHECK program [26] was used to detect marker typ-
ing incompatibilities in pedigree data, which can be due
to errors in pedigree structure or sample switching. All
ambiguous marker genotypes were deleted. On the other
hand, the error-detection approach in Merlin [27] was
used to search for Mendelian inconsistencies within each
of the SNP clusters, discarding genotypes that gave contra-
dictory information about gene flow in a pedigree consid-
ering all available data simultaneously and these
improbable genotypes were removed using the program's
wipe function. The data quality was extremely high, with
successful genotyping obtained for 98.9% of SNP markers
after removing Mendelian errors and genotyping failures.
In contrast, the call rate for STR markers was 96.7%.
Allele frequencies and genetic maps
The analysis of all families combined was done assuming
that all families had the same genetic background, coming
from the same homogeneous (European) population.
Due to the limited number of families (19 families) and
individuals (81 individuals), the allele frequencies were
not estimated separately in each of the three populations
(Spanish, Dutch and American, with 17 individuals, 30
individuals, and 34 individuals, respectively), nor among
the founders (only 17 individuals). We therefore esti-
mated allele frequencies across all individuals pooled. In
order to demonstrate that the estimated allele frequencies
derived from the full data set (ALL frequencies) were
appropriate for the analysis, we compared them with the
frequencies provided by Illumina for each marker, esti-
mated from 82 unrelated CEPH individuals (CEPH fre-
quencies). We found no statistically significant differences
after Bonferroni corrections (data not shown). Focusing
on the highest non parametric LOD score using NPL all
statistics (NPLOD score) values identified, we compared
the results obtained using both types of frequencies and
we found no important differences (the average change
was just 0.13) [see Additional file 1].
In order to obtain more conservative results and avoid
false positives due to specific population differences, all
analyses with SNP markers have been performed using
allele frequencies estimated from the full data set.
Frequency estimation for genomewide scan data with
microsatellites was carried out according to Smith et al.
[16]. For the fine-mapping markers in the candidate
regions, we genotyped an additional 50 unrelated Spanish
controls to obtain better allele frequency estimates. A
genetic map using a total of 4,737 loci for each chromo-
some using 518 meioses derived from 28 CEPH pedigrees
were constructed by Illumina [24], and this CEPH recom-
bination map was used for SNP analysis (excluding pseu-
doautosomal regions). For microsatellite data, we used
the STR genetic map constructed by deCODE Genetics Inc
[28].
Statistical Analysis
Multipoint nonparametric linkage analysis (NPL all statis-
tic) for SNP markers was performed using Merlin and
MINX (Merlin in X) programs [27,29] to calculate Z
means using NPL all statistics (NPLOD score) [30]. For
the parametric linkage analysis (PLA) we assumed a dom-
inant model with a susceptibility allele with population
frequency 0.003. This model is based on Claus et al. [31],
where risks were modelled in seven age-categories and
implemented in 14 liability classes, with separate classes
for unaffected and affected persons [1]. We also consid-
ered a recessive model (RM), under which the risks were
the same as those under the dominant model (DM), but
the susceptibility allele population frequency was 0.08.
Multipoint and singlepoint analyses for the whole family
set and for each family individually were performed using
both CEPH and ALL frequencies, and heterogeneity LOD
scores (HLOD) [32] under dominant or recessive models
and NPLOD scores were calculated. LOD score for indi-
vidual families using per Family option in Merlin software
was also calculated.
Candidate linkage regions were defined as those with
NPLOD scoreswith associated p-values < 0.01 using CEPH
frequencies, but that were still significant (p-values <
0.05) when more conservative analysis (using ALL fre-
quencies) was done. The genomewide scan with microsat-
ellite data and additional fine-mapping microsatellite
data were also analysed using the Merlin program and
parametric and non parametric analyses were performed.
We compared the linkage of a genomewide scan using
SNPs alone (SNP-GWS) with a genomewide scan using
microsatellites alone (STR-GWS) in sixteen families for
which data from both types of scan were available. Para-
metric and non parametric analyses were performed.BMC Genomics 2007, 8:299 http://www.biomedcentral.com/1471-2164/8/299
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The power of linkage analysis and consequently the
expected LOD score is related to the amount of informa-
tion extracted from the map [33]. The information con-
tent (IC) provides a measure of information that can be
extracted from pedigree data using a particular marker set
as compared to an infinitely dense set of markers with
complete genotyping on the entire pedigree. This measure
is a function of marker heterozygosity and the complete-
ness of genotyping, and when multipoint analysis is used,
IC is also a function of density. Information content for
the two marker panels tested (SNP-GWS and STR-GWS)
was calculated with Merlin.
The average r2 between adjacent markers across the genetic
map was 0.11 ± 0.003 in the Illumina III panel (SNP-
GWS), based on 82 CEPH individuals. To determine the
effect of LD between marker loci, two approaches were
taken. Under the first, SNPs in strong LD with other SNPs
(r2 values > 0.2/0.5/0.8) were removed and the data set
reanalysed. Under the second, NPLOD scores (ALL fre-
quencies) were calculated using an approach for model-
ling LD between markers during multipoint analysis [34].
We also performed the comparison using different marker
densities (0.5 cM/1 cM/2 cM).
To evaluate our linkage results, we used Merlin's simula-
tion option to empirically estimate the probability that
the observed proportion of the genome that showed
excess allele sharing could be observed by chance. One
thousand genomewide replicates were analysed under the
null hypothesis of no linkage to breast cancer, and the per-
centage of the genome with an NPLOD score over the
specified threshold was determined in each genomewide
replicate.
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